CN108697694B - Gabaa受体调节剂用于治疗发痒的用途 - Google Patents

Gabaa受体调节剂用于治疗发痒的用途 Download PDF

Info

Publication number
CN108697694B
CN108697694B CN201780008490.1A CN201780008490A CN108697694B CN 108697694 B CN108697694 B CN 108697694B CN 201780008490 A CN201780008490 A CN 201780008490A CN 108697694 B CN108697694 B CN 108697694B
Authority
CN
China
Prior art keywords
unsubstituted
substituted
mice
specifically
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780008490.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN108697694A (zh
Inventor
汉斯·乌尔里希·蔡尔霍弗
威廉·拉尔维纽斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of CN108697694A publication Critical patent/CN108697694A/zh
Application granted granted Critical
Publication of CN108697694B publication Critical patent/CN108697694B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780008490.1A 2016-01-27 2017-01-27 Gabaa受体调节剂用于治疗发痒的用途 Expired - Fee Related CN108697694B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16153035 2016-01-27
EP16153035.7 2016-01-27
EP16178824 2016-07-11
EP16178824.5 2016-07-11
PCT/EP2017/051866 WO2017129801A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Publications (2)

Publication Number Publication Date
CN108697694A CN108697694A (zh) 2018-10-23
CN108697694B true CN108697694B (zh) 2022-12-09

Family

ID=57890845

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780008490.1A Expired - Fee Related CN108697694B (zh) 2016-01-27 2017-01-27 Gabaa受体调节剂用于治疗发痒的用途

Country Status (14)

Country Link
US (3) US10786513B2 (enExample)
EP (1) EP3407886A1 (enExample)
JP (2) JP7115746B2 (enExample)
KR (1) KR102482200B1 (enExample)
CN (1) CN108697694B (enExample)
AU (1) AU2017213154B2 (enExample)
BR (1) BR112018015386A2 (enExample)
CA (2) CA3012791C (enExample)
CL (1) CL2018002023A1 (enExample)
IL (1) IL260775B (enExample)
MX (1) MX388862B (enExample)
SG (1) SG11201806393QA (enExample)
UA (1) UA125463C2 (enExample)
WO (1) WO2017129801A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido
CN112384513A (zh) 2018-04-18 2021-02-19 纽罗塞克医疗公司 Gabaa正变构调节剂化合物、其制备方法和用途
WO2019226820A1 (en) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
HUE060943T2 (hu) * 2018-09-13 2023-04-28 Saniona As A gaba A receptor ligandum
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
CN110004118B (zh) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用
CA3155618A1 (en) * 2019-10-23 2021-04-29 Jed Hubbs Treatment of epileptic conditions with gabaa receptor modulators
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030773A1 (ja) * 2003-09-26 2005-04-07 Dainippon Sumitomo Pharma Co., Ltd. 新規ピラゾロピリミジン誘導体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
EP0915875B1 (en) * 1996-07-25 2003-04-09 MERCK SHARP & DOHME LTD. Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
FR2767692B1 (fr) * 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
AU1253002A (en) 2000-11-10 2002-05-21 Merck Sharp & Dohme Imidazo-triazine derivatives as ligands for gaba receptors
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
WO2005108401A1 (en) * 2004-04-29 2005-11-17 Dov Pharmaceutical, Inc. 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
TW200823215A (en) 2006-08-04 2008-06-01 Merz Pharma Gmbh & Amp Co Kgaa Pyrazolopyrimidines, a process for their preparation and the use as a medicine
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
WO2009021957A2 (en) * 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
AU2010239188B2 (en) 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2456311A4 (en) 2009-07-24 2013-01-23 Concert Pharmaceuticals Inc SUBSTITUTED IMIDASOTRIAZINES
US8809541B2 (en) 2010-08-25 2014-08-19 Neopharm Co., Ltd. Heterocyclic compound, and composition for treating inflammatory diseases using same
US20130331394A1 (en) * 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia
MX362181B (es) * 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
WO2015072853A1 (en) * 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016154031A1 (en) 2015-03-20 2016-09-29 Uwm Research Foundation, Inc. Gabaergic ligands and their uses
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030773A1 (ja) * 2003-09-26 2005-04-07 Dainippon Sumitomo Pharma Co., Ltd. 新規ピラゾロピリミジン誘導体

Also Published As

Publication number Publication date
KR20180118623A (ko) 2018-10-31
BR112018015386A2 (pt) 2019-03-19
KR102482200B1 (ko) 2022-12-27
CA3012791C (en) 2024-01-23
CA3012791A1 (en) 2017-08-03
EP3407886A1 (en) 2018-12-05
RU2018128905A3 (enExample) 2020-03-24
US20210100814A1 (en) 2021-04-08
US20250268912A1 (en) 2025-08-28
US10786513B2 (en) 2020-09-29
US20190134057A1 (en) 2019-05-09
IL260775B (en) 2021-09-30
AU2017213154B2 (en) 2023-02-02
CA3222584A1 (en) 2017-08-03
US12433898B2 (en) 2025-10-07
MX2018009252A (es) 2019-01-21
SG11201806393QA (en) 2018-08-30
US11529359B2 (en) 2022-12-20
JP2022088620A (ja) 2022-06-14
WO2017129801A1 (en) 2017-08-03
JP2019507736A (ja) 2019-03-22
CN108697694A (zh) 2018-10-23
MX388862B (es) 2025-03-20
JP7115746B2 (ja) 2022-08-09
AU2017213154A1 (en) 2018-08-16
UA125463C2 (uk) 2022-03-16
CL2018002023A1 (es) 2019-02-01
RU2018128905A (ru) 2020-02-27

Similar Documents

Publication Publication Date Title
US11529359B2 (en) Use of GABAA receptor modulators for treatment of itch
György et al. Gene transfer with AAV9-PHP. B rescues hearing in a mouse model of usher syndrome 3A and transduces hair cells in a non-human primate
St-Jacques et al. Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors
Dickson et al. Critical role of 5-HT1A, 5-HT3, and 5-HT7 receptor subtypes in the initiation, generation, and propagation of the murine colonic migrating motor complex
Ralvenius et al. Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors
Yu et al. Phosphorylated CRMP2 regulates spinal nociceptive neurotransmission
Vogler et al. Mechanisms underlying long-term synaptic zinc plasticity at mouse dorsal cochlear nucleus glutamatergic synapses
Vargas et al. WASP-1, a canonical Wnt signaling potentiator, rescues hippocampal synaptic impairments induced by Aβ oligomers
US20240390323A1 (en) Novel methods of treating hearing loss
Leibinger et al. Inhibition of microtubule detyrosination by parthenolide facilitates functional CNS axon regeneration
Carlton et al. A critical period of prehearing spontaneous Ca2+ spiking is required for hair‐bundle maintenance in inner hair cells
Kearney et al. Silencing Parkinson’s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability
Stavarache et al. The tumor suppressor PTEN regulates motor responses to striatal dopamine in normal and Parkinsonian animals
JP7697879B2 (ja) 筋肉減少症又は廃用性萎縮症の治療のための組成物
Hou et al. FGF22 deletion causes hidden hearing loss by affecting the function of inner hair cell ribbon synapses
Zhong et al. The Hcn Channel blocker Zd7288 induces Emesis in the least shrew (Cryptotis parva)
RU2781636C2 (ru) Применение модуляторов gabaa-рецептора для лечения зуда
Housley et al. Purinergic signalling: an experimental perspective
HK1262708A1 (en) Use of gabaa receptor modulators for treatment of itch
US12227743B2 (en) Pharmaceutical composition for treatment of diseases associated with upregulated periostin expression or periostin splice variant switching
EP3386510B1 (fr) Derives phosphores pour la prevention ou le traitement des myopathies et traumatismes musculaires
Wu et al. Spinal TREM2/PI3K/Akt signal axis elicits microglial activation and aggravates bone cancer pain
Schweizer Evaluating the Potential of TRESK-Based Gene Therapy for the Treatment of Chronic Pain
Morin Syncytial nuclear domains compartmentalize sarcolemmal dystrophin and determine response to therapy in a Duchenne muscular dystrophy mouse model
Grivet Implication des voies descendantes sérotoninergiques dans le contrôle de la nociception dans la maladie de Parkinson

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262708

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20221209

CF01 Termination of patent right due to non-payment of annual fee